Objective: Anemia, a common complication of chronic kidney disease, usually develops because of erythropoietin defi ciency. Maintaining target hemoglobin (Hb) with minimal variability is a challenge in hemodialysis (HD) patients. The aim of this study is to compare the long-and short-acting erythropoietin erythropoietin stimulating agents such as Mircera and Eprex in achieving these targets. Methods:One hundred (100) patients on regular hemodialysis were complaining of anemia duo to chronic renal failure. The mean age of those patients was 45.66 (17-70 years), divided into two groups: GroupA patients (n=50) that received methoxy polyethyleneglycol-epoetin beta (Mircera) once monthly, and group B (n=50) that received epoetin alfa (Eprex) 3 times per weeks for 6 months, with dose adjustment for individual haemoglobin target (11-12.5g/dl); maximum decrease from baseline 1g/dl. Results:The response rate in the evaluation period was higher in patients treated with methoxypolyethylene glycol-epoetin beta (Mircera) than with epoetin (Eprex) alfa: 36 of 50 (72%) mean Hb concentration (10.51g/dl) versus 29 of 50 (58%) mean Hb concentration (9.81), with statistically signifi cant p-value <0.0001. Conclusions:Treatment with (Mircera) administered intravenously once monthly was superior to treatment with (Eprex) administered subcutaneously three times weekly for maintaining haemoglobin concentrations in patients with chronic kidney disease on hemodialysis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.